X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4741) 4741
Book Chapter (76) 76
Dissertation (25) 25
Conference Proceeding (10) 10
Publication (4) 4
Newspaper Article (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sorafenib (4469) 4469
science & technology (3268) 3268
life sciences & biomedicine (3161) 3161
humans (2691) 2691
niacinamide - analogs & derivatives (1939) 1939
oncology (1843) 1843
hepatocellular carcinoma (1808) 1808
male (1290) 1290
female (1160) 1160
middle aged (1006) 1006
antineoplastic agents - therapeutic use (996) 996
liver neoplasms - drug therapy (913) 913
aged (887) 887
carcinoma, hepatocellular - drug therapy (880) 880
liver cancer (770) 770
treatment outcome (766) 766
phenylurea compounds (760) 760
cancer (736) 736
digestive system diseases (661) 661
animals (629) 629
adult (618) 618
antineoplastic agents (616) 616
liver neoplasms - pathology (612) 612
sunitinib (595) 595
antimitotic agents (587) 587
carcinoma, hepatocellular - pathology (580) 580
phenylurea compounds - therapeutic use (580) 580
care and treatment (570) 570
hepatoma (554) 554
neoplasms (551) 551
niacinamide - therapeutic use (540) 540
cell line, tumor (513) 513
pharmacology & pharmacy (512) 512
antineoplastic agents - pharmacology (475) 475
carcinoma, renal cell - drug therapy (447) 447
antineoplastic agents - adverse effects (439) 439
protein kinase inhibitors - therapeutic use (435) 435
kidney neoplasms - drug therapy (429) 429
phenylurea compounds - administration & dosage (417) 417
pyridines - therapeutic use (413) 413
chemotherapy (412) 412
metastasis (409) 409
niacinamide - administration & dosage (408) 408
gastroenterology & hepatology (400) 400
apoptosis (388) 388
phenylurea compounds - pharmacology (384) 384
benzenesulfonates - therapeutic use (377) 377
medicine & public health (369) 369
renal cell carcinoma (368) 368
niacinamide - pharmacology (363) 363
aged, 80 and over (359) 359
drug therapy (359) 359
prognosis (355) 355
tumors (353) 353
mice (348) 348
analysis (345) 345
retrospective studies (333) 333
antineoplastic agents - administration & dosage (325) 325
cancer therapies (322) 322
disease-free survival (309) 309
kinases (308) 308
phenylurea compounds - adverse effects (308) 308
research (301) 301
cell proliferation - drug effects (299) 299
antineoplastic combined chemotherapy protocols - therapeutic use (295) 295
bevacizumab (295) 295
niacinamide - adverse effects (294) 294
apoptosis - drug effects (293) 293
vascular endothelial growth factor (286) 286
patients (283) 283
protein kinase inhibitors - pharmacology (268) 268
kidney neoplasms - pathology (247) 247
angiogenesis (246) 246
medical prognosis (244) 244
liver neoplasms - metabolism (238) 238
carcinoma, hepatocellular - metabolism (234) 234
carcinoma, hepatocellular - mortality (230) 230
liver neoplasms - mortality (229) 229
pyridines - adverse effects (229) 229
clinical trials (226) 226
neoplasm staging (226) 226
health aspects (225) 225
protein kinase inhibitors - adverse effects (225) 225
survival (225) 225
carcinoma, hepatocellular - therapy (218) 218
liver neoplasms - therapy (218) 218
benzenesulfonates - adverse effects (217) 217
cell biology (212) 212
pyridines - administration & dosage (212) 212
studies (207) 207
carcinoma, renal cell (205) 205
proteins (204) 204
signal transduction - drug effects (204) 204
benzenesulfonates - administration & dosage (203) 203
targeted therapy (200) 200
sorafenib - therapeutic use (199) 199
urologic and male genital diseases (197) 197
liver (195) 195
pyridines - pharmacology (194) 194
development and progression (187) 187
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4428) 4428
Korean (177) 177
Japanese (102) 102
German (57) 57
Chinese (47) 47
French (42) 42
Russian (34) 34
Spanish (22) 22
Portuguese (14) 14
Czech (8) 8
Italian (6) 6
Polish (6) 6
Turkish (3) 3
Slovak (2) 2
Catalan (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 1737, Volume 111, Issue 14, pp. 5319 - 5324
Journal Article
World journal of gastroenterology : WJG, ISSN 1007-9327, 09/2018, Volume 24, Issue 36, pp. 4152 - 4163
Journal Article
Investigational new drugs, ISSN 0167-6997, 4/2018, Volume 36, Issue 2, pp. 332 - 339
Journal Article
Journal Article
BMC cancer, ISSN 1471-2407, 06/2019, Volume 19, Issue 1, pp. 568 - 568
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2007, Volume 13, Issue 6, pp. 1801 - 1809
Purpose: To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib... 
IFN | melanoma | renal cell carcinoma | Sorafenib | combination
Journal Article
Canadian journal of physiology and pharmacology, ISSN 1205-7541, 08/2019, Volume 97, Issue 8, pp. 691 - 698
Journal Article
Cancer science, ISSN 1347-9032, 12/2018, Volume 109, Issue 12, pp. 3993 - 4002
Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint inhibitor (ICI), nivolumab, are used for anticancer therapies against... 
lenvatinib | sorafenib | immunomodulatory activity | anti‐PD‐1 antibody | hepatocellular carcinoma | anti-PD-1 antibody | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | CD8-Positive T-Lymphocytes - cytology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - administration & dosage | Quinolines - administration & dosage | Quinolines - pharmacology | Carcinoma, Hepatocellular - drug therapy | Carcinoma, Hepatocellular - genetics | Antineoplastic Agents - pharmacology | Carcinoma, Hepatocellular - immunology | Immunocompetence | Single-Cell Analysis | Cell Survival - drug effects | Sorafenib - administration & dosage | Liver Neoplasms - genetics | Immunomodulation | Liver Neoplasms - drug therapy | Liver Neoplasms - immunology | Sorafenib - pharmacology | Antineoplastic Agents, Immunological - pharmacology | Xenograft Model Antitumor Assays | Animals | Sequence Analysis, RNA | Phenylurea Compounds - administration & dosage | CD8-Positive T-Lymphocytes - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Phenylurea Compounds - pharmacology | Viral antibodies | Antimitotic agents | RNA sequencing | Cell death | Analysis | Antibodies | Hepatoma | Antineoplastic agents | T cells | Growth factors | Fibroblast growth factor | Laboratories | CD8 antigen | Clinical trials | Hepatocellular carcinoma | Lymphocytes T | Metastasis | Kinases | Macrophages | Cancer therapies | Liver cancer | Ret protein | Lymphocytes | Protein-tyrosine kinase receptors | Fibroblast growth factor receptor 1 | Vascular endothelial growth factor | Protein-tyrosine kinase | Tyrosine | Mortality | Immunodeficiency | Ribonucleic acid--RNA | Monocytes | Thyroid cancer | Immune checkpoint | Response rates | Antitumor activity | Angiogenesis inhibitors | Apoptosis | Tumors | Index Medicus | Original
Journal Article
Acta biomaterialia, ISSN 1742-7061, 05/2018, Volume 72, pp. 248 - 255
Proposed mechanism of miR-375/Sf-LCC NPs for anti-tumor effects and autophagy inhibition in HCC. [Display omitted] Sorafenib is a first-line drug for... 
microRNA | Hepatocellular carcinoma | Nanoparticle | Nanomedicine | Autophagy | Cancer | Engineering | Materials Science | Technology | Engineering, Biomedical | Materials Science, Biomaterials | Science & Technology | Nanoparticles - chemistry | Humans | Coated Materials, Biocompatible - pharmacology | Delayed-Action Preparations - chemistry | MicroRNAs - pharmacokinetics | Sorafenib - chemistry | MicroRNAs - pharmacology | Calcium Carbonate - chemistry | Lipids - chemistry | Carcinoma, Hepatocellular - drug therapy | Lipids - pharmacology | Nanoparticles - therapeutic use | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Liver Neoplasms - pathology | Calcium Carbonate - pharmacokinetics | Coated Materials, Biocompatible - pharmacokinetics | Sorafenib - pharmacokinetics | Liver Neoplasms - drug therapy | Coated Materials, Biocompatible - chemistry | Sorafenib - pharmacology | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Lipids - pharmacokinetics | Mice, Nude | Carcinoma, Hepatocellular - pathology | Liver Neoplasms - metabolism | Mice | Calcium Carbonate - pharmacology | MicroRNAs - chemistry | Carcinoma, Hepatocellular - metabolism | Antimitotic agents | Nanoparticles | Pharmacy | Analysis | Calcium carbonate | Drugstores | Hepatoma | Antineoplastic agents | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2018, Volume 379, Issue 25, pp. 2417 - 2428
Journal Article